NIH Cuts Threaten Future of American Medical Innovation

Published April 6, 2025 · Updated March 2026

Update March 2026: When I first wrote this post in April 2025, the NIH funding cuts were alarming but still unfolding. Since then, the picture has grown considerably darker. As of mid-2025, roughly 2,300 NIH grants totaling nearly $3.8 billion had been terminated outright, including at least 160 active clinical trials in cancer, HIV/AIDS, and chronic disease research. The administration’s proposed FY2026 budget calls for a roughly 40 percent reduction in NIH support — a level that, adjusted for inflation, would be lower than at any point in the past 25 years. Congress has largely resisted the steepest proposed cuts, but budget maneuvers including front-loading grants and capping indirect costs are already suppressing the number of new research awards regardless of what the final appropriations figure says. The argument I made here in the spring of 2025 has only become more urgent since.

As a physician and public health expert, I have seen firsthand how transformative U.S. investment in medical research can be. The main engine of that funding has been the National Institutes of Health, which until recently commanded a budget of roughly $47 billion flowing to government, academic, and private industry researchers across the country. That investment fuels discovery, turns promising ideas into life-saving treatments, and anchors the United States as the global leader in biomedical innovation. That leadership is now being dismantled in ways that will take a generation to repair — and I believe the public deserves a clear-eyed account of what is actually at stake. This post explains why NIH funding matters, what the current cuts are already costing us, and what a serious commitment to national health would actually require.

Why Does NIH Funding Matter for Medical Breakthroughs?

This isn’t about politics. It’s about patients and the pipeline that brings laboratory discoveries to their bedside. NIH dollars don’t just pay for pipettes and petri dishes, or for researchers to keep busy publishing scientific papers. They pay the human beings who become the next generation of medical innovation — supporting university spinoffs, funding the highest-risk early research that private investors won’t touch, and sustaining the clinical trial infrastructure that tells us whether a promising drug or vaccine actually works at scale. When the NIH freezes grants or slashes budgets, everything slows: not enough staff to do the work, no funding for the supplies and equipment that clinical trials require, cures delayed or abandoned entirely. Studies continue to show that every dollar invested in NIH research generates substantial downstream returns in economic output and reduced healthcare costs — returns that vanish when the investment stops.

What Are the Consequences of the NIH Budget Cuts Today?

We saw the power of NIH investment with mRNA vaccine development — years of early-stage government support for the kind of foundational research only the public sector will take a risk on. That research ultimately saved millions of lives and, when studied in clinical trials, gave us the critical epidemiological parameters we needed to guide public health policy: the attack rate, the secondary attack rate, the infectious period, and the incubation period in people with and without prior immunity.

Yet that kind of forward-thinking investment is now under direct attack. Start-ups tackling mental health, rare pediatric diseases, cancer treatment, and new antibiotics are frozen in limbo. Talented young scientists are leaving research careers entirely because there is no money to support their work. According to recent reporting, cancer research funding fell by 31 percent in the first quarter of 2025 compared to the same period the previous year — a drop with consequences that will not be visible for years but will nonetheless be real and irreversible.

The Hidden Mechanism: How Budget Maneuvers Are Suppressing Research Even Without Formal Cuts

One of the least-discussed but most consequential aspects of the current situation is that the damage to NIH-funded research is happening through mechanisms that don’t always show up in the headline budget numbers. In February 2025, the NIH announced a 15 percent cap on indirect costs — the overhead payments that allow universities and research hospitals to maintain the labs, equipment, and administrative infrastructure that make science possible. A federal judge ruled this move illegal in April 2025, but the administration appealed, leaving research institutions in prolonged uncertainty. Separately, the NIH shifted to a policy of front-loading or “forward-funding” grants, distributing multiyear grants in a lump sum rather than annually. The practical effect is that even if Congress holds the NIH’s top-line budget stable for FY2026, the agency will have fewer new awards to make because so much of its available funding was disbursed in advance. As the American Cancer Society Cancer Action Network put it, this represents a de facto cut despite nominal flat funding. The result is a system that looks intact from the outside while its ability to support new science quietly erodes from within — exactly the kind of slow institutional unraveling that is hardest to reverse once it takes hold. This pattern is not unlike what I have described in the context of public health system collapse more broadly — visible only in retrospect, when the losses have already compounded. 

Could the U.S. Lose Its Edge in Biomedical Research?

The United States does not have a monopoly on good ideas or talented scientists. Countries including China are rapidly scaling up their own biotech industries, investing heavily in the exact research areas — genomics, infectious disease, oncology, AI-assisted drug discovery — where American cuts are creating vacuums. NIH’s own historical budget data makes clear how unprecedented the proposed reductions are in the modern era. If the United States cedes this ground, the consequences are not abstract. We lose jobs. We lose innovation. We lose domestic access to therapies developed with American taxpayer investment. We lose the geopolitical leverage that comes from being the world’s leading source of medical discovery. And we eventually lose lives — slowly, invisibly, in the form of diseases that were never cured and outbreaks that were never prevented because the science was never funded.

What Should Be Done to Protect U.S. Medical Innovation?

The administration’s stated goal is to “Make America Healthy Again.” That objective demands more investment in science, not less. Undermining NIH doesn’t just shrink budgets; it shrinks the future. A 40 percent cut to the agency that has been the backbone of American biomedical progress for 80 years is not a reform — it is a dismantling. The argument that this can be done more efficiently, or that waste is the primary problem to solve, does not withstand scrutiny when 160 active clinical trials are being terminated mid-cycle and early-career scientists are abandoning research careers by the thousands. If we are serious about health, competitiveness, and basic human decency, we need to treat science as the national asset it demonstrably is — and we need to say so clearly and loudly, now, while there is still time to reverse course. For a broader account of how anti-science has become policy across public health agencies, see my conversation with Dr. Tom Farley on how anti-science becomes policy. 

If this post raised questions about the broader erosion of U.S. public health infrastructure, my piece on whether the U.S. could face a post-Soviet-style public health collapse examines the systemic risks in more depth. For ongoing coverage of CDC and federal public health policy, explore the full writing archive.